Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

CompletedOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

July 6, 2018

Study Completion Date

August 30, 2020

Conditions
Neuroma
Interventions
DEVICE

Neurocap®

NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.

Trial Locations (16)

17822

Geisinger Clinic, Danville

19107

The Philadelphia Hand Center (affiliated to Thomas Jefferson Hospital), Philadelphia

23219

Virginia Commonwealth University Medical Center, Richmond

60389

BG Trauma Center Frankfurt am Main GmbH, Frankfurt am Main

85004

Arizona Center for Hand Surgery, Phoenix

94063

Stanford Medical Center Hand and Upper Limb Center, Redwood City

94114

Buncke Clinic, San Francisco

97239

Veterans affairs Medical Center Portland, Portland

19104-6061

University of Pennsylvania, Philadelphia

Unknown

Clinique Chirurgicale Victor Hugo Paris, Paris

Ospedale San Guiseppe Milano, Milan

Parc Sanitari Sant Joan de Deu, Barcelona

Sahlgrenska University Hospital Gothenburg, Gothenburg

University Hospital Linköping, Linköping

University Hospital Lund - Department of Hand Surgery, Malmo

Birmingham Hand Centre, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Polyganics BV

INDUSTRY

NCT02993276 - Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma | Biotech Hunter | Biotech Hunter